

IFW



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Application of)	
Donald J. Zack, <i>et al.</i>)	Examiner: TBA
Serial No. 10/618,084)	Group Art Unit: TBA
Filed: July 14, 2003)	
For: NEURONAL AND RETINAL GENE EXPRESSION)	
PATTERNS)	Atty. Dkt. No. 01107.00370

INFORMATION DISCLOSURE STATEMENT
37 C.F.R. § 1.97(e)(1)


Commissioner for Patents
Post Office Box 1450
Alexandria, Virginia 22313-1450

Submitted herewith is one (1) sheet of Form PTO-1449. A copy of each of the references listed therein is enclosed. It is respectfully requested that the Examiner make his/her consideration of each of these documents formally of record.

This Information Disclosure Statement is filed pursuant to 37 C.F.R. § 1.97 (e)(1). The undersigned certifies that all items of information contained in the Information Disclosure Statement were cited in a communication from a foreign patent office in a counterpart foreign application and that this communication was not received by the undersigned more than thirty days prior to the filing of this Information Disclosure Statement. It is believed that no fee is required to ensure consideration of the cited references by the Examiner. However, if a fee is deemed necessary, the Commissioner is authorized to charge Deposit Account 19-0733.

Respectfully submitted,

Dated: August 31, 2004

By: 
Sarah A. Kagan
Registration No. 32,141

Banner & Witcoff, Ltd.
Customer No. 22907

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	10/618,084
Filing Date	July 14, 2003
First Named Inventor	Donald J. ZACK
Art Unit	
Examiner Name	
Attorney Docket Number	001107.00370

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		PRESTA, L.G. <i>et al.</i> , "Humanization of an Anti-Vascular Endothelial Growth Factor Monoclonal Antibody for the Therapy of Solid Tumors and Other Disorders," <i>Cancer Research</i> , (15 Oct. 1997), Vol. 57, No. 20, pp. 4593-4599	
		SCHENK, D. <i>et al.</i> , "Immunization with amyloid-b attenuates Alzheimer-disease-like pathology in the PDAPP mouse," <i>Nature</i> , (08 Jul. 1999), Vol. 400, pp. 173-177	
		KRENZ, N.R. <i>et al.</i> , "Neutralizing Intraspinous Nerve Growth Factor Blocks Automatic Dysreflexia Caused by Spinal Cord Injury," <i>J. Neuroscience</i> (01 Sept. 1999), Vol. 19, No. 17, pp. 7405-7414	
		BROSAMLE, C. <i>et al.</i> , "Regeneration of Lesioned Corticospinal Tract Fibers in the Adult Rat Induced by a Recombinant, Humanized IN-1 Antibody Fragment," <i>J. Neuroscience</i> , (01 Nov. 2000), Vol. 20, No. 21, pp. 8061-8068	
		MEAD <i>et al.</i> , "Evaluation of Anti-TGF-b2 Antibody as a New Postoperative Anti-Scarring Agent in Glaucoma Surgery," <i>Investigative Ophthalmology & Visual Science</i> , (August 2003), Vol. 44, No. 8, pp. 3394-3401	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.